



## Article

# The relationship between zinc intake and serum/plasma zinc concentration in adults: a systematic review and dose-response meta-analysis by the EURRECA Network

Lowe, Nicola M, Warthon Medina, Marisol, Stammes, Anna-Louise, Patel, Sujata, Souverein, Olga W, Dullemeijer, Carla, Serra-Majem, Lluís, Nissensohn, Mariela and Hall Moran, Victoria

Available at <http://clock.uclan.ac.uk/5753/>

*Lowe, Nicola M ORCID: 0000-0002-6934-2768, Warthon Medina, Marisol, Stammes, Anna-Louise, Patel, Sujata, Souverein, Olga W, Dullemeijer, Carla, Serra-Majem, Lluís, Nissensohn, Mariela and Hall Moran, Victoria ORCID: 0000-0003-3165-4448 (2012) The relationship between zinc intake and serum/plasma zinc concentration in adults: a systematic review and dose-response meta-analysis by the EURRECA Network. British Journal of Nutrition, 108 (11). pp. 1962-1971. ISSN 0007-1145*

It is advisable to refer to the publisher's version if you intend to cite from the work.

<http://dx.doi.org/10.1017/S0007114512004382>

For more information about UCLan's research in this area go to <http://www.uclan.ac.uk/researchgroups/> and search for <name of research Group>.

For information about Research generally at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the [policies](#) page.

1 The relationship between zinc intake and serum/plasma zinc concentration in adults. A  
2 systematic review and dose-response meta-analysis by the EURRECA Network

Nicola M Lowe<sup>1\*</sup>, Marisol Warthon Medina<sup>1</sup>, Anna-Louise Stammers<sup>1</sup>, Sujata Patel<sup>1</sup>, Olga W  
Soverein<sup>2</sup>, Carla Dullemeijer<sup>2</sup>, Lluís Serra-Majem<sup>3</sup>, Mariela Nissensohn<sup>3</sup>, Victoria Hall  
Moran<sup>4</sup>

<sup>1</sup> International Institute of Nutritional Sciences and Food Safety Studies, University of  
Central Lancashire, Preston PR1 2HE, UK ([NMLowe@uclan.ac.uk](mailto:NMLowe@uclan.ac.uk); [ASkinner@uclan.ac.uk](mailto:ASkinner@uclan.ac.uk);  
[MWathonmedinal@uclan.ac.uk](mailto:MWathonmedinal@uclan.ac.uk); [SPatel26@uclan.ac.uk](mailto:SPatel26@uclan.ac.uk))

<sup>2</sup> Division of Human Nutrition, Wageningen University, P.O. Box 8129, 6700 EV,  
Wageningen, the Netherlands ( [olga.soverein@wur.nl](mailto:olga.soverein@wur.nl); [Carla.Dullemeijer@wur.nl](mailto:Carla.Dullemeijer@wur.nl))

3 <sup>3</sup> Department of Clinical Sciences, University of Las Palmas de Gran Canaria, Spain  
4 ([lserra@dcc.ulpgc.es](mailto:lserra@dcc.ulpgc.es); [mnissensohn@acciones.ulpgc.es](mailto:mnissensohn@acciones.ulpgc.es))

<sup>4</sup> Maternal & Infant Nutrition & Nurture Unit, University of Central Lancashire, Preston PR1  
2HE, UK. ([vlmoran@uclan.ac.uk](mailto:vlmoran@uclan.ac.uk))

Short title: Zinc intake and plasma zinc concentration

5

6 \*Corresponding Author:

7 Nicola Lowe, Reader in Nutritional Science. International Institute of Nutritional Sciences  
8 and Applied Food Safety Studies, Darwin Building, University of Central Lancashire, Preston  
9 PR1 2HE, UK

10 phone: 01772 893599

11 fax 01772 892925

12

13 Key words

14 EURRECA, zinc, dose-response, systematic review, meta-analysis.

15

16

17

18

19

20 **Abstract**

21 Dietary zinc recommendations vary widely across Europe due to the heterogeneity of  
22 approaches used by expert panels. Under the EURRECA consortium a protocol was designed  
23 to systematically review and undertake meta-analyses of research data to create a database  
24 that includes “best practice” guidelines which can be used as a resource by future panels  
25 when setting micronutrient recommendations. As part of this process, the objective of the  
26 present study was to undertake a systematic review and meta-analysis of previously published  
27 data describing the relationship between zinc intake and status in adults. Searches were  
28 performed of literature published up to February 2010 using MEDLINE, Embase, and  
29 Cochrane Library. Data extracted included population characteristics, dose of zinc, duration  
30 of study, dietary intake of zinc, and mean concentration of zinc in plasma or serum at the end  
31 of the intervention period. An intake-status regression coefficient ( $\beta$ ) was estimated for each  
32 individual study, and pooled meta-analysis undertaken. The overall pooled  $\beta$  for zinc  
33 supplementation on serum/plasma zinc concentrations from RCTs and observational studies  
34 was 0.08 (95% CI 0.05, 0.11;  $p < 0.0001$ ;  $I^2$  84.5%). An overall  $\beta$  of 0.08 means that for every  
35 doubling in zinc intake, the difference in zinc serum or plasma concentration is  $2^\beta$  ( $2^{0.08} =$   
36 1.06), which is 6%. Whether the dose-response relationship, as provided in this paper, could  
37 be used as either qualitative or quantitative evidence to substantiate the daily zinc intake dose  
38 necessary to achieve normal or optimal levels of biomarkers for zinc status, remains a matter  
39 of discussion.

40

41

42

43

44

45

46

## 47 **Introduction**

48 Dietary zinc recommendations vary widely across Europe due to the heterogeneity of  
49 approaches used by expert panels <sup>(1)</sup>. There is a need for a harmonised approach that is  
50 transparent and based on the best quality data and methods available. Traditionally, the  
51 factorial approach is used in the determination of zinc requirements. This method seeks to  
52 estimate the zinc intake required to meet physiological requirements for growth, metabolism  
53 and tissue repair while replacing obligatory losses. An alternative approach is to examine the  
54 dose-response relationship between intake and biomarkers of status and also between intake  
55 and health outcomes. This information could then be integrated using a mathematical model  
56 to provide an insight into the level of zinc intake required for optimal health based on a range  
57 of parameters and indices of health that are known to be dependent upon dietary zinc intake  
58 <sup>(2)</sup>. **To this end, the members of the European Micronutrient Recommendations Aligned**  
59 **(EURRECA) Network of Excellence** have undertaken a series of systematic reviews of zinc-  
60 intake-status relationships, **according to rigorous protocols defined by consortium members**  
61 **and external experts** <sup>(2)</sup>. This paper presents the results of the systematic review and meta-  
62 analysis of the dose response relationship between dietary zinc intake and zinc **status using**  
63 **novel methodology developed by members the EURRECA consortium.**

64 The assessment of zinc status is notoriously problematic for zinc, as a sensitive,  
65 specific biomarker for zinc has not yet been identified <sup>(3)</sup>. A systematic review and meta-  
66 analysis of biomarkers of zinc status was undertaken in 2009 <sup>(4)</sup>. For many putative  
67 biomarkers **(such as the zinc concentrations found in the cellular components of whole blood)**  
68 there were insufficient data to arrive at a definitive conclusion regarding their efficacy as a  
69 biomarker of zinc status, however plasma (or serum) zinc concentration was responsive to  
70 both zinc supplementation and zinc depletion and is the most widely reported biomarker for  
71 zinc. **Hair and urine zinc concentrations were also considered to be potentially useful**  
72 **biomarkers in response to zinc supplementation.**

73 The purpose of this study was to systematically and quantitatively assess the dose  
74 response relationships relevant to deriving zinc recommendations based on intervention  
75 studies, cohort (nested case control) studies and cross-sectional studies. The specific  
76 questions to be addressed were; what is the effect of intake on indicators of exposure or body  
77 stores (i.e. biomarkers)? What factors affect this relationship?

78           The data used in this meta-analysis were extracted from published studies (RCTs,  
79   prospective cohort studies, nested case-control studies and cross-sectional), performed in  
80   healthy adult and elderly populations, reporting the relationship between zinc status (plasma  
81   or serum zinc, hair or urine zinc concentration) and intake from supplements, fortified diets  
82   or natural food diets.

83

## 84   **Methods**

### 85   *Search strategy*

86   This research was conducted within the framework of the European Micronutrient  
87   Recommendations Aligned (EURRECA) Network of Excellence that aims to identify the  
88   micronutrient requirements for optimal health in European populations ([www.eurreca.org](http://www.eurreca.org)).  
89   This research was part of a wider review process to identify studies assessing the effect of  
90   zinc intake on different outcomes (biomarkers of zinc status and health outcomes). The wider  
91   searches were performed of literature published up to and including February 2010 using  
92   Ovid MEDLINE, Embase (Ovid), and the Cochrane Library (CENTRAL) using search terms  
93   for ('study designs in humans') AND (zinc) AND (intake OR status). Both indexing and text  
94   terms were used and languages included were restricted to those spoken in the EURRECA  
95   Network (English, Dutch, French, German, Hungarian, Italian, Norwegian, Polish, Spanish,  
96   Greek, and Serbian.). The full Ovid MEDLINE search strategy can be found in Table 1.  
97   Reference lists of retrieved articles and published literature reviews were also checked for  
98   relevant studies. Authors were contacted to request missing data or clarify methods or results.  
99   The search process is illustrated in Figure 1.

100

### 101   *Criteria for the consideration of studies for this review*

102   Included studies were RCTs, prospective cohort studies, nested case-control studies and  
103   cross-sectional studies in healthy human populations that supplied zinc supplementation  
104   (RCTs) or measured dietary zinc intake with either a validated food frequency questionnaire,  
105   a dietary history method, a 24-hour recall method for at least 3 days, or a food record/diary  
106   for at least 3 days (observational studies). Studies had to be conducted in apparently healthy  
107   adult and elderly (human) populations aged  $\geq 18$  years and supplied zinc supplementation  
108   either as capsules or part of a fortified meal. If supplemental zinc was provided as a  
109   component of a fortified meal, studies were only considered acceptable if zinc was the only

110 constituent that was different between treatment groups. Biomarkers of zinc status included  
111 plasma/serum, urine and hair zinc concentrations. Only studies that reported sufficient data or  
112 had sufficient data obtainable from the authors to estimate  $\beta$  and  $SE(\beta)$  for the assumed linear  
113 relation on the  $\log_e$ - $\log_e$  scale were included. Studies were excluded if they were a group  
114 RCT (community trial), or were commentaries, reviews, or duplicate publications from the  
115 same study. Studies were excluded if adults were hospitalised, had a chronic disease or if  
116 supplemental zinc was provided for less than 2 weeks.

117

### 118 *Selection of articles*

119 Of 4719 identified articles in the wider search on zinc intake, status and priority health  
120 outcomes in all populations, 2557 were excluded based upon screening of the title and  
121 abstract. Two independent reviewers screened 10% of the abstracts in duplicate and any  
122 discrepancies were discussed before screening the remaining references. Following  
123 subdivision into appropriate population groups the full texts of the 1231 manuscripts were  
124 assessed to determine inclusion and exclusion by two independent reviewers and  
125 disagreements rectified through discussion. 1147 studies were excluded because they did not  
126 meet the inclusion criteria. Of the remaining 84 studies, 54 studies were excluded as they  
127 related either zinc intake or status directly to a health endpoint, but they had not investigated  
128 the relationship between zinc intake and zinc related to biomarkers. A further 17 studies were  
129 excluded from the meta-analysis because study participants were not healthy, insufficient data  
130 was reported, data was duplicated, or the dosage and duration was unclear. For the purpose of  
131 this meta-analysis, 10 RCTs and 3 observational studies remained. The characteristics of the  
132 included studies are presented in Table 2 and Table 3 respectively.

133

### 134 *Data extraction*

135 For each of the identified manuscripts, data was extracted independently by two reviewers  
136 into a standardized database. Extracted data included population characteristics, dose of zinc  
137 in intervention and placebo supplements, duration of the study, dietary intake of zinc, and  
138 mean concentration of zinc in plasma or serum at the end of the intervention period.  
139 Serum/plasma zinc concentrations were converted to  $\mu\text{mol/L}$  when applicable.

140

### 141 *Data synthesis*

142 Two RCTs that reported data for two zinc-treated groups and two control groups were treated  
143 as two independent estimates in the analysis <sup>(5; 6)</sup>. Where RCTs provided outcome data for  
144 two or more zinc-treated group, they were included as separate estimates in the meta-analysis  
145 <sup>(7; 8; 9; 10; 11)</sup>. Where zinc status was measured at different time points within the same  
146 population only the final measure was used in the analysis <sup>(12; 13)</sup>. One observational study  
147 reported data from males and females and these were treated as two estimates in the meta-  
148 analysis <sup>(14)</sup>. If dietary intake of zinc (in addition to the intervention) was not reported in the  
149 RCTs, a value of 9.7 mg/day **was imputed, which was** the mean dietary intake level of the  
150 RCTs that did report dietary zinc intake. As mean baseline serum/plasma zinc concentrations  
151 were infrequently reported in the RCTs, the serum/plasma zinc concentrations in the control  
152 group were used as a proxy of the baseline serum/plasma zinc concentrations for our  
153 analyses.

154

#### 155 *Statistical analyses*

156 A stratified random effects meta-analysis was conducted using STATA version 11 (**College**  
157 **Station, TX**), with one subgroup combining the evidence from RCTs and the other subgroup  
158 combining the evidence from observational studies. As serum/plasma zinc levels have been  
159 reported to decline with age <sup>(15)</sup>, a separate stratified random effects meta-analysis compared  
160 zinc intake and status according to age in RCTs (< 55 years and ≥ 55 years). In addition,  
161 stratified meta-analyses were also conducted on dose of zinc (<35 mg/day and ≥ 35 mg/day)  
162 and trial duration (in weeks). **It was not possible** to perform a stratified meta-analysis for  
163 gender, because most studies included both men and women and data were not available at  
164 the individual level.

165 The transformations used to derive coherent single-study estimates from the available  
166 summary statistics per study have been described elsewhere <sup>(16)</sup>. In short, an intake-status  
167 regression coefficient ( $\beta$ ) for each individual study **was estimated from the mean**  
168 **serum/plasma zinc concentrations**, based on the assumption of a linear relation on the log<sub>e</sub>-  
169 log<sub>e</sub>-scale (natural logarithm of intake versus natural logarithm of status). Algebraically  
170 deriving an estimate from each study of the regression coefficient ( $\hat{\beta}$ ) and its standard error  
171 (SE( $\hat{\beta}$ )) **enabled a comparison** of the results from studies with heterogeneously reported  
172 associations and effects. The overall pooled  $\hat{\beta}$  and SE( $\hat{\beta}$ ) **was calculated** using random effects  
173 meta-analysis, which estimates the between-study variance using the method of DerSimonian  
174 and Laird <sup>(17)</sup>. **This was then used** to modify the weights used to calculate the summary

175 estimate. Residual heterogeneity between studies was evaluated using the  $I^2$  statistic. To  
176 evaluate potential sources of heterogeneity, the variables study duration, age, gender and zinc  
177 dose were added simultaneously to a meta-regression model as continuous variables. The  
178 statistical transformations to obtain  $\beta$ 's and  $SE(\beta)$ 's were performed using GenStat version  
179 13-SP2 (VSN International Ltd. Hemel Hempstead, UK) and the meta-analysis was performed  
180 using STATA version 11.0, with statistical significance defined as  $P < 0.05$ .

181

### 182 *Assessment of risk of bias in included studies*

183 In order to assess the quality of the included studies and the risk of bias, indicators of internal  
184 validity were collected during data extraction (Table 3). Based on the indicators two  
185 independent reviewers assessed the overall risk of bias and disagreements resolved by  
186 discussion. The criteria for judging these indicators were adapted from the Cochrane  
187 Handbook for Systematic Reviews<sup>(18)</sup>.

## 188 **Results**

189 Twenty estimates of zinc intake and serum/plasma zinc status in 10 RCTs and four estimates  
190 in 3 observational studies were eligible for meta-analysis. All studies were published between  
191 1979 and 2010. Although plasma/serum, urine and hair zinc concentrations were included as  
192 markers of status in the systematic review protocol, only plasma/serum zinc concentration  
193 was reported universally and sufficiently frequently to be used in the meta-analysis. Most  
194 studies included, but did not differentiate between, males and females, but three studies  
195 included only females<sup>(19; 9; 20)</sup>, two included only males<sup>(13; 8)</sup> and one provided both male and  
196 female data<sup>(14)</sup>. Studies were conducted in Europe (n=7), North America (n=3), South Asia  
197 (n=1), East Asia (n=1) and Australasia (n=1) and ages of participants ranged from 18 to 106  
198 years.

199 All but one RCTs used a parallel design. Boukaïba and colleagues employed a cross-  
200 over RCT design<sup>(6)</sup>. The RCTs included 1285 participants in total with sample sizes ranging  
201 from 5-201. The median duration of the trials was 25 weeks (range 2-52 weeks). In 9 studies  
202 zinc was supplemented alone at doses ranging from 15-135.3 mg/day and in 1 study zinc was  
203 provided within a multi-micronutrient supplement<sup>(12)</sup>. Most studies (n=7) provided the zinc  
204 supplements in the form of zinc gluconate, but others used zinc sulphate<sup>(21)</sup>, zinc acetate<sup>(7)</sup>,  
205 or zinc carnosine<sup>(11)</sup>. Habitual zinc intakes ranged from 5.4-10.8 mg/day (where data was  
206 provided).



207 The observational studies included 1184 participants in total with sample sizes  
208 ranging from 170-500. Zinc intake was measured using a combination of FFQ and 24 hour  
209 recall, or 24 hour recall alone and values ranged from 8.6-12.2 mg/day. The meta-analysis of  
210 available studies suggested that zinc supplementation was associated with increased  
211 serum/plasma zinc concentrations. The estimated effect for zinc supplementation on  
212 serum/plasma zinc concentrations from RCTs and observational studies was 0.08 (95% CI  
213 0.05, 0.11;  $p < 0.0001$ ;  $I^2$  84.5%) (Fig 2). When data sets were grouped according to study  
214 design, only the RCTs showed a significant effect size (0.09 95% CI 0.07, 0.120;  $p < 0.0001$ ;  
215  $I^2$  79.1%).

216 Since a base- $e$  logarithmic transformation was applied to the zinc intake and  
217 serum/plasma zinc concentration before calculation of the study-specific  $\beta$ 's, the overall  $\beta$   
218 represents the difference in the  $\log_e$  transformed predicted value of serum/plasma zinc status  
219 for each one-unit difference in the  $\log_e$  transformed value in zinc intake. Therefore, an overall  
220  $\beta$  of 0.08 means that for every doubling in zinc intake, the difference in zinc serum or plasma  
221 concentration is  $2^{\beta}$  ( $2^{0.08} = 1.06$ ), which is 6%. This means that a person with a zinc intake of  
222 14 mg/day has a zinc serum/plasma concentration that is 6% higher than a person who has a  
223 zinc intake of 7 mg/day (Fig 3).

224 As plasma/serum zinc concentrations have been reported to decline with age <sup>(15)</sup>, a  
225 separate subgroup analysis compared zinc intake and status according to age in RCTs (< 55  
226 years and  $\geq 55$  years). Two studies for which mean serum/plasma zinc values were given for  
227 adults whose ages spanned both age groups were excluded from this analysis <sup>(12; 11)</sup>. A  
228 stronger effect size was found in adults aged under 55 years (0.14 95% CI 0.04, 0.24;  
229  $p < 0.005$ ;  $I^2$  92.1%) compared to adults aged 55 years and over (0.09 95% CI 0.07, 0.11;  
230  $p < 0.0001$ ;  $I^2$  32.8%), although care should be taken with interpreting this finding as the  
231 younger age group analysis is based on only three estimates in two studies. Stratifying the  
232 analysis for dose of zinc (<35 mg/day and  $\geq 35$  mg/day) revealed a stronger effect size for a  
233 zinc dose  $\geq 35$ mg/d (0.14 95% CI 0.08, 0.21;  $p < 0.0001$ ;  $I^2$  85.2%) compared to <35mg/d  
234 (0.09 95% CI 0.07, 0.10;  $p < 0.005$ ;  $I^2$  27.6%). Similar effect sizes were demonstrated for  
235 study duration (0-12 weeks 0.13 CI 0.05, 0.20  $I^2$  92.4% and > 12 weeks 0.10 CI 0.07, 0.12  $I^2$   
236 75.8%).

237 To evaluate potential sources of heterogeneity, the variables duration, age, gender and  
238 dose were added simultaneously to a meta-regression model as continuous variables. The  
239 analysis revealed that only zinc dose was a statistically significant determinant of the overall

240 beta. The model explained 50% of between-study variance and the residual variation due to  
241 heterogeneity was reduced to 48.2%.

242

243 Table 4 summarises the internal validity of the included studies, assessed as described  
244 in the methods section. The risk of bias was high in 5 out of the 10 papers (21; 6; 22; 23; 11) .  
245 Papers were given a high risk of bias rating due to insufficient information provided on  
246 sequence generation and/or allocation, drop-outs and funding bodies.

247

## 248 Discussion

249 The current study is unique in providing an estimate of the dose-response relationship of zinc  
250 intake and serum/plasma zinc concentrations in adults. A meta-analysis of 20 estimates in 10  
251 RCTs and 4 estimates in 3 observational studies found that zinc supplementation produced a  
252 statistically significant increase in serum/plasma zinc concentrations and provided an  
253 estimate of the dose-response relationship between zinc intake and serum/plasma  
254 concentrations. An overall  $\beta$  of 0.08 means that for every doubling in zinc intake, the  
255 difference in zinc serum or plasma concentration is 6%. In other words, an adult with a zinc  
256 intake of 14 mg/day has a zinc serum/plasma concentration that is 6% higher than a person  
257 who has a zinc intake of 7 mg/day. This association was slightly stronger when considering  
258 only the RCTs, as no observational studies found a significant association between zinc  
259 intake and plasma zinc concentrations. The intake-status regression coefficient for the  
260 observational studies is likely to be attenuated by random and intake-related errors in  
261 assessing dietary zinc intake (24), whereas in RCTs zinc intake can be considered as fixed at  
262 each level of dosage and random errors arise only through assessment of biomarkers.

263 The studies included in this meta-analysis were different in a number of aspects, such  
264 as using various designs, follow-up times, zinc doses, and populations. Therefore, it is no  
265 surprise that, when combining these studies in a meta-analysis, a large heterogeneity is  
266 observed between the studies ( $I^2 = 84.5\%$   $p=0.0001$ ). This between-study heterogeneity may  
267 be caused by methodological factors, such as differences in study population characteristics  
268 (age, socio-economic status) or differences in doses of provided zinc (amount, one or more  
269 doses per day, study duration). When considering some key variables (study duration, zinc  
270 dose, age, and gender) in a meta-regression model, only dose explained some between-study  
271 heterogeneity. An individual participant data meta-analysis may have provided a more  
272 conclusive explanation of the between-study heterogeneity in this meta-analysis. However,

273 this type of analysis would involve the input of raw individual participant data provided by  
274 the original study investigators for re-analysis and combination in a pooled analysis and as  
275 such would be a major undertaking in terms of time, costs, and collaboration. Moreover, an  
276 inability to include individual participant data from all relevant studies could introduce  
277 selection bias. The meta-analytic approach used in this paper is not an attempt to accurately  
278 describe the biological relation between actual zinc intake and zinc concentrations in blood  
279 under strict experimental conditions and on an individual level, but rather to simulate a dose-  
280 response relationship between zinc intake and status that is useful for surveillance studies  
281 with a public health point of view and, as such, deliberately incorporates the differences  
282 between dietary assessment methods, laboratory assessment methods and participant  
283 characteristics to ensure a broad external validity. Thus, the heterogeneity reflects the lack of  
284 standardization of methods and the true heterogeneity between study populations and  
285 necessarily enters as uncertainty into the application of such data for public health purposes  
286 <sup>(25)</sup>.

287 To conduct this meta-analysis some assumptions related to the availability of the  
288 required data or related to statistical issues had to be made. First, when two or more  
289 intervention groups were compared to the same control group (5 RCTs), independence of  
290 estimates was assumed. As a consequence bias may have been introduced, by either  
291 increasing the estimates of the intervention effect (if the control group values were in fact  
292 lower), or decreasing the estimates of the intervention effect (if the control group values were  
293 higher). Second, the meta-analysis required transformations of the intake and biomarker data  
294 to a common scale, as the studies included in this meta-analysis had different ways of  
295 reporting **the relation between zinc and serum/plasma zinc concentration**. The different ways  
296 of reporting by transformation of both the intake and biomarker data were standardized to  
297 double  $\log_e$ -scale, which allowed the derivation of a standardized estimate from each study of  
298 the regression coefficient and its standard error as a basis for comparing these  
299 heterogeneously reported results. A linear relationship on the double  $\log_e$ -scale was also  
300 assumed. This transformation allowed the pooling of beta values and enable these to be  
301 reported as a dose-response relationship between zinc intake and serum/plasma zinc  
302 concentrations <sup>(16)</sup>.

303 The meta-analyses were conducted within the context of the EURRECA project as a  
304 means to provide additional evidence for underpinning reference values for zinc intake of  
305 populations. **This dose-response relationship methodology may be used as either qualitative  
306 or quantitative evidence to substantiate the daily zinc intake dose necessary to achieve normal**

307 or optimal levels of biomarkers for zinc status. The dose-response relationship between zinc  
308 intake and plasma zinc concentration is of course subject to the debate around the usefulness  
309 of plasma/serum zinc concentration as a biomarker of zinc status, and the it's predictive value  
310 for relevant functional health outcomes, such as markers of immune function.

311 The relationship observed between serum/plasma zinc concentration and zinc intake  
312 may have been weakened by the limitation of this particular biomarker for zinc status. It is  
313 well established that plasma zinc concentration can fall in response to factors unrelated to  
314 zinc status or dietary zinc intake, such as infection, inflammation, exercise, stress or trauma  
315 (26). Conversely, tissue catabolism during starvation can release zinc into the circulation,  
316 causing a transient increase in circulating zinc levels. Six studies used non-fasted blood  
317 samples in their analyses (5; 7; 27; 20; 11; 14). As postprandial plasma zinc concentrations have  
318 been reported to fall up to 19% (28), the inclusion of these studies may have weakened the  
319 observed relationship between zinc intake and status. Whilst all studies included in the  
320 analysis were undertaken in individuals without chronic disease or severe protein-energy  
321 malnutrition, other factors such as stress, infection and inflammation may also have gone  
322 unreported. In addition, serum zinc concentration has been reported to decrease with age (15).  
323 Clearly such confounders have a strong influence on the interpretation of plasma zinc  
324 concentrations. However, as more sensitive indices of zinc status have yet to be identified,  
325 plasma serum zinc remains by far the most commonly used biomarker of zinc status (4).

326 In conclusion, the current study presents the application of a novel technique to  
327 analyse data from 10 RCT's and 3 observational studies reporting the relationship between  
328 zinc intake and serum/plasma zinc concentration. This meta-analysis has provided an  
329 estimate of the dose-response relationship between zinc intake and serum/plasma zinc  
330 concentration in adults and elderly populations. Based on 24 estimates among 2469  
331 participants, the results indicate that a doubling of zinc intake increases plasma/serum levels  
332 by 6%. There is a high level of heterogeneity in the data obtained from the studies included in  
333 this meta-analysis. Analysis of the factors that may contribute to this, namely study duration,  
334 zinc dose, age, and gender, indicated that zinc dose was able to explain 50% of this  
335 heterogeneity. This novel method of analyzing intake/biomarker relationships may be useful  
336 for the setting of future dietary zinc recommendations.

337

### 338 **Acknowledgements**

339 The work reported herein has been carried out within the EURRECA Network of Excellence  
340 ([www.eurreca.org](http://www.eurreca.org)) which is financially supported by the Commission of the European

341 Communities, specific Research, Technology and Development (RTD) Programme Quality  
342 of Life and Management of Living Resources, within the Sixth Framework Programme,  
343 contract no. 036196. This report does not necessarily reflect the Commission's views or its  
344 future policy in this area. There are no conflicts of interest for any of the authors of the  
345 present study. NL, MWM, S-LS, VM, MN collected and analysed the data, SP and LSM  
346 were also involved in the data analysis. OS and CD developed the statistical techniques and  
347 advised on their application to the present study. All authors were involved in writing the  
348 manuscript.

349 The original conception of the systematic review was undertaken by the EURRECA Network  
350 and coordinated by partners based at Wageningen University (WU), the Netherlands and the  
351 University of East Anglia (UEA), United Kingdom. Susan Fairweather-Tait (UEA), Lisette  
352 de Groot (WU), Pieter van't Veer (WU), Kate Ashton (UEA), Amélie Casgrain (UEA),  
353 Adriëne Cavelaars (WU), Rachel Collings (UEA), Rosalie Dhonukshe-Rutten (WU), Esmée  
354 Doets (WU), Linda Harvey (UEA) and Lee Hooper (UEA) designed and developed the  
355 review protocol and search strategy.

356 The authors would also like to thank Joseph Saavedra, Nick Kenworthy, Sarah Richardson-  
357 Owen, Hannah Eichmann and Christine Cockburn for assistance with data extraction and  
358 Fiona Dykes for helpful discussions.

359

360

## 361 **References**

- 362 1. Doets EL, de Wit LS, Dhonukshe-Rutten RAM *et al.* (2008) Current micronutrient  
363 recommendations in Europe: towards understanding their differences and similarities.  
364 *European Journal of Nutrition* **47**, 17-40.
- 365 2. Matthys C vTVP, de Groot L, Hooper L, Cavelaars AE, Collings R, Dhonukshe-Rutten R,  
366 Harvey LJ, Casgrain A, Rollin F, Contor L. (2011) EURRECA's Approach for Estimating  
367 Micronutrient Requirements. *Int J Vitam Nutr Res.* **81**, 256-263.
- 368 3. King JC (2011) Zinc: an essential but elusive nutrient. *Am J Clin Nutr* **94**, 679S-684S.
- 369 4. Lowe NM, Fekete K & Decsi T (2009) Methods of assessment of zinc status in humans: a  
370 systematic review. *American Journal of Clinical Nutrition* **89**, 2040S-2051S.

- 371 5. Abdulla M & Svensson S (1979) Effect of oral zinc intake on delta-aminolaevulinic acid  
372 dehydratase in red blood cells. *Scandinavian Journal of Clinical & Laboratory Investigation*  
373 **39**, 31-36.
- 374 6. Boukaiba N, Flament C, Acher S *et al.* (1993) A physiological amount of zinc  
375 supplementation: Effects on nutritional, lipid, and thymic status in an elderly population.  
376 *American Journal of Clinical Nutrition* **57**, 566-572.
- 377 7. Bogden JD, Oleske JM, Lavenhar MA *et al.* (1988) Zinc and immunocompetence in  
378 elderly people: effects of zinc supplementation for 3 months. *The American journal of*  
379 *clinical nutrition* **48**, 655-663.
- 380 8. Feillet-Coudray C, Meunier N, Rambeau M *et al.* (2005) Long-term moderate zinc  
381 supplementation increases exchangeable zinc pool masses in late-middle-aged men: The  
382 Zenith Study. *American Journal of Clinical Nutrition* **82**, 103-110.
- 383 9. Feillet-Coudray C, Meunier N, Bayle D *et al.* (2006) Effect of zinc supplementation on in  
384 vitro copper-induced oxidation of low-density lipoproteins in healthy French subjects aged  
385 55-70 years: The Zenith study. *British Journal of Nutrition* **95**, 1134-1142.
- 386 10. Hininger-Favier I, Andriollo-Sanchez M, Arnaud J *et al.* (2007) Age- and sex-dependent  
387 effects of long-term zinc supplementation on essential trace element status and lipid  
388 metabolism in European subjects: The Zenith Study. *British Journal of Nutrition* **97**, 569-  
389 578.
- 390 11. Sakagami M, Ikeda M, Tomita H *et al.* (2009) A zinc-containing compound, Polaprezinc,  
391 is effective for patients with taste disorders: Randomized, double-blind, placebo-controlled,  
392 multi-center study. *Acta Oto-Laryngologica* **129**, 1115-1120.
- 393 12. Preziosi P, Galan P, Herbeth B *et al.* (1998) Effects of supplementation with a  
394 combination of antioxidant vitamins and trace elements, at nutritional doses, on biochemical  
395 indicators and markers of the antioxidant system in adult subjects. *Journal of the American*  
396 *College of Nutrition* **17**, 244-249.
- 397 13. Sullivan VK, Burnett FR & Cousins RJ (1998) Metallothionein expression is increased in  
398 monocytes and erythrocytes of young men during zinc supplementation. *Journal of Nutrition*  
399 **128**, 707-713.
- 400 14. Sanchez C, Lopez-Jurado M, Planells E *et al.* (2009) Assessment of iron and zinc intake  
401 and related biochemical parameters in an adult Mediterranean population from southern  
402 Spain: influence of lifestyle factors. *Journal of Nutritional Biochemistry* **20**, 125-131.
- 403 15. Rea IM (1989) Sex and age-changes in serum zinc levels. *Nutrition Research* **9**, 121-125.

- 404 16. Souverein OW, Dullemeyer C, van TVP *et al.* (2012) Transformations of summary  
405 statistics as input in meta-analysis for linear dose-response models on a logarithmic scale: a  
406 methodology developed within EURRECA. *BMC Med Res Methodol* **12**, 57.
- 407 17. DerSimonian R & Laird N (1986) Meta-analysis in clinical trials. *Control Clin Trials* **7**,  
408 177-188.
- 409 18. Higgins J & Green Se (2009) *Cochrane Handbook for Systematic Reviews for*  
410 *Interventions, version 5.0.2 (updated September 2009)*
- 411 19. Gibson RS, Heath ALM, Limbaga MLS *et al.* (2001) Are changes in food consumption  
412 patterns associated with lower biochemical zinc status among women from Dunedin, New  
413 Zealand? *British Journal of Nutrition* **86**, 71-80.
- 414 20. Chandyo RK, Strand TA, Mathisen M *et al.* (2009) Zinc deficiency is common among  
415 healthy women of reproductive age in Bhaktapur, Nepal. *Journal of Nutrition* **139**, 594-597.
- 416 21. Abdulla M, Behbehani A & Dashti H (1989) Dietary intake and bioavailability of trace  
417 elements. *Biological Trace Element Research* **21**, 173-178.
- 418 22. Preziosi P, Galan P, Herbeth B *et al.* (1998) Effects of supplementation with a  
419 combination of antioxidant vitamins and trace elements, at nutritional doses, on biochemical  
420 indicators and markers of the antioxidant system in adult subjects. *Journal of the American*  
421 *College of Nutrition* **17**, 244-249.
- 422 23. Sullivan VK, Burnett FR & Cousins RJ (1998) Metallothionein expression is increased in  
423 monocytes and erythrocytes of young men during zinc supplementation. *Journal of Nutrition*  
424 **128**, 707-713
- 425 24. Kipnis V, Subar AF, Midthune D *et al.* (2003) Structure of dietary measurement error:  
426 Results of the OPEN biomarker study. *American Journal of Epidemiology* **158**, 14-21.
- 427 25. Dullemeyer C, Souverein O, Doets E *et al.* (Under review) Systematic review with dose-  
428 response meta-analyses between vitamin B12 intake and EURRECA's prioritized biomarkers  
429 of vitamin B12 including randomized controlled trials and observational studies in adults and  
430 elderly.
- 431 26. King JC (1990) Assessment of zinc status. *Journal of Nutrition* **120**, 1474-9.
- 432 27. Prasad AS, Beck FW, Bao B *et al.* (2007) Zinc supplementation decreases incidence of  
433 infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. *The*  
434 *American journal of clinical nutrition* **85**, 837-44
- 435 28. Lowe NM, Woodhouse LR & King JC (1998) A comparison of the short-term kinetics of  
436 zinc metabolism in women during fasting and following a breakfast meal. *British Journal of*  
437 *Nutrition* **80**, 363-370.

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454 **Figure Legends**

455 **Figure 1** Study selection process for systematic review

456 **Figure 2** Random effects meta-analyses of RCTs and observational studies evaluating the  
457 pooled effect of dietary zinc on serum/plasma zinc in adults. Beta values (◆) represent the  
458 regression coefficients for the linear association between  $\log_e$  transformed zinc intake and  
459  $\log_e$  transformed serum/plasma zinc status.

460 **Figure 3** Serum/plasma zinc concentration ( $\mu\text{mol/L}$ ) as a function of dietary zinc intake  
461 ( $\text{mg/day}$ ), estimated by random-effects meta-analyses of RCTs of adults

462

463



464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

Table 1. Ovid MEDLINE search strategy.

<i>No.</i>	<i>Search term</i>	<i>Results</i>
1	randomized controlled trial.pt.	280821
2	controlled clinical trial.pt.	79998
3	randomized.ab.	196604
4	placebo.ab.	117891
5	clinical trials as topic.sh.	146242
6	randomly.ab.	145491
7	trial.ab.	203467
8	randomised.ab.	38423
9	6 or 3 or 7 or 2 or 8 or 1 or 4 or 5	734511
10	(animals not (human and animals)).sh.	4482479
11	9 not 10	642665
12	(cohort* or "case control*" or cross-sectional* or "cross sectional" or case-control* or prospective or "systematic review*").mp.	768885
13	exp meta-analysis/ or exp multicenter study/ or follow-up studies/ or prospective studies/ or intervention studies/ or epidemiologic studies/ or case-control studies/ or exp cohort studies/ or longitudinal studies/ or cross-sectional studies/	1013635
14	13 or 12	1203767
15	14 not 10	1154385
16	11 or 15	1599094
17	((zinc or zn or zinc sulphate or zinc gluconate or zinc acetate or methionine or zinc isotope*) adj3 (intake* or diet* or supplement* or deplet* or status or serum or plasma or leukocyte or concentration* or expos* or fortif* or urine or hair)).ti,ab.	16681
18	Nutritional Support/ or Dietary Supplements/ or nutritional requirements/ or Breast feeding/ or exp infant food/ or bottle feeding/ or infant formula/	63098
19	exp Nutritional Status/ or exp Deficiency Diseases/ or supplementation/ or diet supplementation/ or dietary intake/ or exp diet restriction/ or exp mineral intake/ or Diet/ or Food, Fortified/ or nutrition assessment/ or Nutritive Value/	176014
20	(intake* or diet* or supplement* or deplet* or status or serum or plasma or leukocyte or concentration* or expos* or fortif* or urine or hair).ti,ab.	3166092
21	18 or 19 or 20	3263114
22	zinc/	41027
23	22 and 21	20745
24	23 or 17	26943
25	24 and 16	2410

**Table 2:** Randomised controlled trials (n=10) reporting the effect of dietary zinc intake on serum/plasma zinc status in adults.

First author, year, country	Gender, age	Treatment groups	Micronutrient type	Duration	Status marker reported [analytic method]
Abdulla, 1979 Sweden (5)	Mean age 25 y. SD, age range, gender not reported	<i>Study 1</i> Placebo (n=5) 135.3mg/d Zn (n=7) <i>Study 2</i> Placebo (n=8) 45mg/d Zn (n=7)	Zinc sulphate	12 wk	Plasma Zn [AAS]
Bodgen, 1988 USA (6)	Males and females aged 60- 89 y	Placebo (n=36) 15 mg/d Zn (n=36) 100 mg/d Zn (n=31)	Zinc acetate	3 mo	Plasma Zn [AAS]
Boukaïba, 1993	Males and females aged 73-106 y	<i>BMI ≤ 21</i> Placebo (n=21)	Zinc gluconate	8 wk	Serum Zn [AAS]

France (4)		20mg/d Zn (n=21) <i>BMI ≥ 24</i> Placebo (n=23) 20mg/d Zn (n=23)			
Preziosi, 1998 France (12)	Males and females aged 35-60 y	Placebo (n=200) Multi-micronutrient supplement (20mg/d Zn) (n=201)	Zinc gluconate	3 & 6 mo	Serum Zn [AAS]
Sullivan, 1998 USA (11)	Males aged 19- 35 y	Placebo (n=13) 50mg/d Zn (n=13)	Zinc gluconate	15 d	Plasma Zn [AAS]
Feillet-Coudray, 2005 France (8)	Males aged 58-68 y	Placebo (n=16) 15 mg/d Zn (n=16) 30 mg/d Zn (n=16)	Zinc gluconate	6 mo	Plasma Zn [ICP-MS]
Feillet-Coudray, 2006 France (7)	Females aged 55-70 y	Placebo (n=16) 15 mg/d Zn (n=16) 30 mg/d Zn (n=15)	Zinc gluconate	6 mo	Serum Zn [ICP-MS]

Hininger-Favier, 2007 France, UK, Italy (9)	Males and females aged 55-85 y	<i>Age 55-70y</i> Placebo (n=63) 15mg/d Zn (n=60) 30mg/d Zn (n=65)  <i>Age &gt;70 y</i> Placebo (n=67) 15 mg/d Zn (n=66) 30 mg/d Zn (n=66)	Zinc gluconate	6 mo	Serum Zn [AAS]
Prasad, 2007 USA (21)	Males and females aged 55-87 y	Placebo (n=25) 45 mg/d Zn (n=24)	Zinc gluconate	12 mo	Plasma Zn [AAS]
Sakagami, 2009 Japan (10)	Males and females aged 21-77 y	Placebo (n=28) 17 mg/d Zn (n=27) 34 mg/d Zn (n=26) 68 mg/d Zn (n=28)	Zinc carnosine	12 wk	Serum Zn [AAS]

AAS atomic absorption spectroscopy; ICP-MS inductively coupled plasma mass spectrometry

**Table 3:** Observational studies (n=3) reporting the association between dietary zinc intake and serum/plasma zinc status in adults.

<b>First author, year, country</b>	<b>N</b>	<b>Mean (SD) zinc intake (mg/day)</b>	<b>Mean (SD) plasma/serum zinc (<math>\mu\text{mol/L}</math>)</b>	<b>Zinc intake (source)</b>	<b>Zinc intake (assessment)</b>	<b>Zinc status biomarker [analytical method]</b>
Gibson 2001 (New Zealand) (17)	330 females aged 18-40 y	10.44 (3.51)	12.00 (1.36)	Diet	FFQ & 24 hr recall	Serum zinc [AAS]
Chandyo, 2009 (Nepal) (16)	500 females aged 13-35 y	8.6 (3.3)	8.5 (2.4)	Diet	FFQ & 24 hr recall (2 days)	Plasma zinc [ICP-AES]
Sánchez 2009 (Spain) (13)	170 males aged	12.24 (7.16)	17.48 (6.68)	Diet	24 hr recall (2	Plasma zinc [AAS]

25-60 y			days)
184 females aged	9.07 (4.40)	16.32 (6.21)	
25-60 y			

---

AAS atomic absorption spectroscopy; ICP-MS inductively coupled plasma mass spectrometry

**Table 4 Assessment of validity of included RCTs reporting zinc intake and serum/plasma zinc in adults**


<b>Study</b>	<b>Adequate sequence generation</b>	<b>Adequate Blinding</b>	<b>Dropouts adequate and outcome data complete</b>	<b>Funder adequate</b>	<b>Compliance check &amp; results</b>	<b>Dose check &amp; results</b>	<b>Dietary intake data reported &amp; results</b>	<b>Status reproducibility reported</b>	<b>Similarity of most &amp; least exposed groups at baseline</b>	<b>Lack of other potential threats to validity</b>	<b>Overall risk of bias</b>
Abdulla 1979	no	no	unclear	no	unclear	unclear	nr	No	yes	no	High
Bodgen 1988	yes	yes	yes	yes	nr	yes	yes	no	yes	yes	Low
Boukaiba 1993	unclear	yes	yes	unclear	yes	nr	yes	nr	yes	yes	High
Preziosi 1998	yes	yes	yes	unclear	yes	yes	nr	yes	yes	yes	High
Sullivan 1998	unclear	unclear	yes	yes	yes	nr	nr	no	yes	yes	High
Feillet-Coudray 2005	unclear	yes	yes	yes	yes	yes	unclear	yes	yes	yes	Low
Feillet-Coudray	unclear	yes	yes	yes	yes	yes	yes	yes	yes	yes	Low




2006											
Hininger-Favier 2007	unclear	yes	unclear	yes	yes	yes	yes	yes	yes	yes	Low
Prasad 2007	yes	yes	yes	yes	yes	yes	nr	yes	yes	yes	Low
Sakagami 2009	unclear	yes	yes	unclear	nr	yes	nr	yes	yes	unclear	High

nr: not reported

Figure 1 Study selection process for systematic review



**Figure 2** Random effects meta-analyses of RCTs and observational studies evaluating the pooled effect of dietary zinc on serum/plasma zinc in adults. Beta values (◆) represent the regression coefficients for the linear association between  $\log_e$  transformed zinc intake and  $\log_e$  transformed serum/plasma zinc status.



1: RCTs; 2: Observational studies

Figure 3 Serum/plasma zinc concentration ( $\mu\text{mol/L}$ ) as a function of dietary zinc intake ( $\text{mg/day}$ ), estimated by random-effects meta-analyses of RCTs of adults

